{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:37:42Z","timestamp":1783381062673,"version":"3.54.6"},"reference-count":34,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Nowadays, it is possible to identify a group at increased risk of preeclampsia (PE) and fetal growth restriction (FGR) using the principles of the Fetal Medicine Foundation (FMF). It has been established for several years that acetylsalicylic acid (ASA) reduces the incidence of PE and FGR in high-risk populations. This study aimed to evaluate the implementation of ASA use after the first-trimester screening in a Polish population without chronic hypertension, as well as its impact on perinatal complications. Material and methods: A total of 874 patients were enrolled in the study during the first-trimester ultrasound examination. The risk of PE and FGR was assessed according to the FMF guidelines, which include the maternal history, mean arterial pressure (MAP), uterine artery pulsatility index (UtPI), pregnancy-associated plasma protein A (PAPP-A) and placental growth factor (PLGF). Among patients with a risk higher than &gt;1:100, ASA was administered at a dose of 150 mg. Perinatal outcomes were assessed among the different groups. Results: When comparing women in the high-risk group with those in the low-risk group, a statistically significantly higher risk of pregnancy complications was observed in the high-risk group. These complications included pregnancy-induced hypertension (PIH) (OR 3.6 (1.9\u20137)), any PE (OR 7.8 (3\u201320)), late-onset PE (OR 8.5 (3.3\u201322.4)), FGR or small for gestational age (SGA) (OR 4.8 (2.5\u20139.2)), and gestational diabetes mellitus type 1 (GDM1) (OR 2.4 (1.4\u20134.2)). The pregnancies in the high-risk group were more likely to end with a cesarean section (OR 1.9 (1.2\u20133.1)), while the newborns had significantly lower weights (&lt;10 pc (OR 2.9 (1.2\u20136.9)), &lt;3 pc (OR 10.2 (2.5\u201341.7))). Conclusions: The first-trimester screening test for PE and FGR is a necessary and effective tool in identifying high-risk pregnancies. ASA prophylaxis among high-risk patients may have the most beneficial effect. Furthermore, this screening tool may significantly reduce the incidence of early-onset PE (eo-PE).<\/jats:p>","DOI":"10.3390\/jcm12175582","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:10:22Z","timestamp":1693203022000},"page":"5582","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Screening for Preeclampsia and Fetal Growth Restriction in the First Trimester in Women without Chronic Hypertension"],"prefix":"10.3390","volume":"12","author":[{"given":"Piotr","family":"Tousty","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Fraszczyk-Tousty","sequence":"additional","affiliation":[{"name":"Department of Neonatology and Neonatal Intensive Care, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4300-4557","authenticated-orcid":false,"given":"Anna","family":"Golara","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Zahorowska","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"S\u0142awi\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, Public Clinical Hospital No. 2, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8279-5585","authenticated-orcid":false,"given":"Sylwia","family":"Dzidek","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2007-9011","authenticated-orcid":false,"given":"Hanna","family":"Jasiak-J\u00f3\u017awik","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Nawceniak-Balczerska","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2881-9769","authenticated-orcid":false,"given":"Agnieszka","family":"Kordek","sequence":"additional","affiliation":[{"name":"Department of Neonatology and Neonatal Intensive Care, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9847-6589","authenticated-orcid":false,"given":"Ewa","family":"Kwiatkowska","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Cymbaluk-P\u0142oska","sequence":"additional","affiliation":[{"name":"Department of Reconstructive Surgery and Gynecological Oncology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Torb\u00e9","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1504-3639","authenticated-orcid":false,"given":"Sebastian","family":"Kwiatkowski","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1097\/AOG.0b013e3181a45b25","article-title":"Hypertensive disorders and severe obstetric morbidity in the United States","volume":"113","author":"Kuklina","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"ref_2","first-page":"CD004659","article-title":"Antiplatelet agents for preventing pre-eclampsia and its complications","volume":"2019","author":"Duley","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_3","unstructured":"(2023, July 17). Hypertension in Pregnancy: Diagnosis and Management NICE Guideline. Available online: www.nice.org.uk\/guidance\/ng133."},{"key":"ref_4","unstructured":"(2023, July 17). Low-Dose Aspirin Use for the Prevention of Preeclampsia and Related Morbidity and Mortality. ACOG. Available online: https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2021\/12\/low-dose-aspirin-use-for-the-prevention-of-preeclampsia-and-related-morbidity-and-mortality."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/uog.19112","article-title":"Screening for pre-eclampsia by maternal factors and biomarkers at 11\u201313 weeks\u2019 gestation","volume":"52","author":"Tan","year":"2018","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103.e1","DOI":"10.1016\/j.ajog.2015.08.034","article-title":"Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11\u201313 weeks gestation","volume":"214","author":"Wright","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/uog.17399","article-title":"Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11\u201313 weeks\u2019 gestation","volume":"49","author":"Wright","year":"2017","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000341264","article-title":"Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers","volume":"33","author":"Akolekar","year":"2013","journal-title":"Fetal Diagn. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/uog.7628","article-title":"Hypertensive disorders in pregnancy: Screening by biophysical and biochemical markers at 11\u201313 weeks","volume":"35","author":"Poon","year":"2010","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000341712","article-title":"Combined Screening for Preeclampsia and Small for Gestational Age at 11\u201313 Weeks","volume":"33","author":"Poon","year":"2012","journal-title":"Fetal Diagn. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000321694","article-title":"Prediction of Small-for-Gestation Neonates from Biophysical and Biochemical Markers at 11\u201313 Weeks","volume":"29","author":"Karagiannis","year":"2010","journal-title":"Fetal Diagn. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"585.e1","DOI":"10.1016\/j.ajog.2017.07.038","article-title":"Aspirin for Evidence-Based Preeclampsia Prevention trial: Effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history","volume":"217","author":"Poon","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/uog.19077","article-title":"Prediction and prevention of small-for-gestational-age neonates: Evidence from SPREE and ASPRE","volume":"52","author":"Tan","year":"2018","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijgo.12802","article-title":"The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention","volume":"145","author":"Poon","year":"2019","journal-title":"Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","article-title":"Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice","volume":"72","author":"Brown","year":"2018","journal-title":"Hypertension"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/uog.15884","article-title":"Consensus definition of fetal growth restriction: A Delphi procedure","volume":"48","author":"Gordijn","year":"2016","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"685.e1","DOI":"10.1016\/j.ajog.2017.08.110","article-title":"Aspirin for Evidence-Based Preeclampsia Prevention trial: Influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia","volume":"217","author":"Wright","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41581-019-0119-6","article-title":"Pre-eclampsia: Pathogenesis, novel diagnostics and therapies","volume":"15","author":"Phipps","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ajog.2019.05.044","article-title":"Placental bed research: I. The placental bed: From spiral arteries remodeling to the great obstetrical syndromes","volume":"221","author":"Brosens","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Aouache, R., Biquard, L., Vaiman, D., and Miralles, F. (2018). Oxidative Stress in Preeclampsia and Placental Diseases. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051496"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000336662","article-title":"Early administration of low-dose aspirin for the pre-vention of preterm and term preeclampsia: A systematic review and meta-analysis","volume":"31","author":"Roberge","year":"2012","journal-title":"Fetal. Diagn. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajog.2016.09.076","article-title":"The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: Systematic review and meta-analysis","volume":"216","author":"Roberge","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ajog.2019.11.1243","article-title":"Chronic hypertension in pregnancy","volume":"222","author":"Battarbee","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000512335","article-title":"Performance of the FMF First-Trimester Preeclampsia-Screening Algorithm in a High-Risk Population in The Netherlands","volume":"48","author":"Zwertbroek","year":"2021","journal-title":"Fetal Diagn. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"204.e1","DOI":"10.1016\/j.ajog.2020.08.008","article-title":"Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: The Great Obstetrical Syndromes cohort study","volume":"224","author":"Boutin","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/14767058.2017.1378332","article-title":"Validation of Fetal Medicine Foun-dation algorithm for prediction of pre-eclampsia in the first trimester in an unselected Brazilian population","volume":"32","author":"Lobo","year":"2019","journal-title":"J. Matern.-Fetal Neonatal Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.preghy.2021.05.010","article-title":"Clinical implementation of pre-eclampsia screening in the first trimester of pregnancy","volume":"25","author":"Cordisco","year":"2021","journal-title":"Pregnancy Hypertens."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tousty, P., Fraszczyk-Tousty, M., Dzidek, S., Jasiak-J\u00f3\u017awik, H., Michalczyk, K., Kwiatkowska, E., Cymbaluk-P\u0142oska, A., Torb\u00e9, A., and Kwiatkowski, S. (2023). Low-Dose Aspirin after ASPRE\u2014More Questions Than Answers? Current International Approach after PE Screening in the First Trimester. Biomedicines, 11.","DOI":"10.3390\/biomedicines11061495"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/uog.17455","article-title":"Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11\u201313 weeks\u2019 gestation: Comparison with NICE guidelines and ACOG recommendations","volume":"49","author":"Wright","year":"2017","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/uog.19039","article-title":"Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: Results of SPREE","volume":"51","author":"Tan","year":"2018","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/1471-0528.16477","article-title":"Aspirin should be targeted to those who need it","volume":"128","author":"Green","year":"2021","journal-title":"BJOG Int. J. Obstet. Gynaecology."},{"key":"ref_33","first-page":"w14498","article-title":"First trimester combined screening for preeclampsia and small for gestational age\u2014A single centre experience and validation of the FMF screening algorithm","volume":"147","author":"Mosimann","year":"2017","journal-title":"Swiss. Med. Wkly."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/AOG.0b013e3181e9322a","article-title":"Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-analysis","volume":"116","author":"Bujold","year":"2010","journal-title":"Obstet. Gynecol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5582\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:39:57Z","timestamp":1760128797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,27]]},"references-count":34,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jcm12175582"],"URL":"https:\/\/doi.org\/10.3390\/jcm12175582","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,27]]}}}